Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zika Vaccine Trials Could Test Multiple Candidates Vs. Common Control Group

Executive Summary

FDA and NIH officials propose three strategies for clinical trials, saying it will be challenging to identify the most promising candidates; Sanofi and Walter Reed researchers note challenges in vaccine development, including manufacturing scale up.

You may also be interested in...



Chief Scientist At US FDA Is Hinton As Borio Moves To White House

Luciana Borio is detailed to National Security Council; FDA promotes Denise Hinton to acting chief scientist.

Pandemic Vaccines Probably Can’t Use Accelerated Approval – US FDA Chief Scientist

That’s not because the agency doesn’t want to get products cleared as fast as possible, Luciana Borio says; it’s because the pathway remains elusive for many pandemic treatments in the absence of surrogates due to largely undeveloped science.

Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract

Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel